What are the investment strengths of SELLAS Life Sciences Group Inc (SLS)?

Minimal debt (0.01 D/E) and 43.1M working capital provide clean balance sheet for partnership deals or financing R&D-focused spend (58% of opex) with lean overhead suggests efficient capital deployment toward value-creating activities

What are the investment risks for SELLAS Life Sciences Group Inc (SLS)?

17-month runway at current burn forces near-term dilution - 26.1M raised TTM via financing already Zero revenue with -84% ROE and -66% ROA means total dependence on external capital until commercialization

SELLAS Life Sciences Group Inc

SLS

—

Build a strategy around SLS

SELLAS Life Sciences Group Inc AI Insights

Informational only. Not investment advice.

As of 2025-12-19

Snapshot

Zero revenue pre-commercial biotech burning 30.6M TTM cash with 44.3M remaining - ~17 months runway at current rate[Cash and Equivalents]
R&D spend of 15.7M TTM is 58% of operating expenses - lean G&A (2.9M) signals capital efficiency for stage[Research and Development]
Trading at 5.9x book value with zero revenue - market pricing significant pipeline optionality[P/B Ratio]

Watch Triggers

Cash and Equivalents: Falls below 25M or burn rate exceeds 35M annualized — Signals imminent dilutive financing within 6-9 months
Total Revenue: Any revenue recognition from partnerships or milestones — Would validate pipeline and extend runway without dilution
Research and Development: Significant increase or decrease from 15.7M TTM run rate — Indicates pipeline advancement or program cuts

Bull Case

Minimal debt (0.01 D/E) and 43.1M working capital provide clean balance sheet for partnership deals or financing

Debt to EquityWorking Capital

R&D-focused spend (58% of opex) with lean overhead suggests efficient capital deployment toward value-creating activities

Research and DevelopmentGeneral and Administrative Expense

Bear Case

17-month runway at current burn forces near-term dilution - 26.1M raised TTM via financing already

Cash Flow from Continuing Financing ActivitiesFree Cash Flow

Zero revenue with -84% ROE and -66% ROA means total dependence on external capital until commercialization

Total RevenueROEROA

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

35%

Leverage SLS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Binary catalyst risk: pipeline success/failure will determine 3-5x upside or 80%+ downside

1-3ymed

Zero revenue means 100% valuation tied to pipeline
17-month cash runway creates financing pressure
P/B of 5.9x implies high expectations already priced

TTM revenue: $0, FCF: -30.6MCash: 44.3M vs burn: 30.6M TTMMarket cap 255.8M on 45.6M equity

Valuation Context

Caveats

Public Strategies Rankings

See how SELLAS Life Sciences Group Inc ranks across different investment strategies.

Leverage SLS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

SLS Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	Industry Percentile
Market Cap	$0	—
Enterprise Value	$0	—
P/E Ratio	0.00	—
Total Revenue - TTM	$0	—
Earnings Per Share (diluted) - TTM	$0.00	—
Operating Margin - TTM	0%	—
Net Margin - TTM	0%	—
Free Cash Flow - TTM	$-28.39M	—
Return on Common Equity - TTM	-66.9%	—
Beta 5Y (Monthly)	unknown	—

SLS Dividend History

No dividends

SLS Stock Splits

3 stock splits

11/08/1950:1 split

01/02/1830:1 split

11/14/1620:1 split

SLS SEC Filings

Filing Date	Report Date	Report Type	Filing Link
03/19/26	12/31/25	10-K	0001390478-26-000003
11/12/25	09/30/25	10-Q	0001390478-25-000020
08/12/25	06/30/25	10-Q	0001390478-25-000016
05/13/25	03/31/25	10-Q	0001390478-25-000008
03/20/25	12/31/24	10-K	0001390478-25-000003
11/13/24	09/30/24	10-Q	0001390478-24-000021
08/13/24	06/30/24	10-Q	0001390478-24-000015
05/14/24	03/31/24	10-Q	0001390478-24-000010
03/28/24	12/31/23	10-K	0001390478-24-000004
11/09/23	09/30/23	10-Q	0001390478-23-000024
08/10/23	06/30/23	10-Q	0001390478-23-000019
05/11/23	03/31/23	10-Q	0001390478-23-000012
03/16/23	12/31/22	10-K	0001390478-23-000005
11/14/22	09/30/22	10-Q	0001390478-22-000028
08/11/22	06/30/22	10-Q	0001390478-22-000020
05/12/22	03/31/22	10-Q	0001390478-22-000012
03/31/22	12/31/21	10-K	0001390478-22-000006
11/12/21	09/30/21	10-Q	0001390478-21-000036
08/12/21	06/30/21	10-Q	0001390478-21-000030
05/13/21	03/31/21	10-Q	0001390478-21-000017
03/23/21	12/31/20	10-K	0001390478-21-000007
11/13/20	09/30/20	10-Q	0001390478-20-000037
08/13/20	06/30/20	10-Q	0001390478-20-000026
05/14/20	03/31/20	10-Q	0001390478-20-000014
03/13/20	12/31/19	10-K	0001390478-20-000007
11/14/19	09/30/19	10-Q	0001390478-19-000056
08/14/19	06/30/19	10-Q	0001390478-19-000045
05/15/19	03/31/19	10-Q	0001390478-19-000030
03/22/19	12/31/18	10-K	0001390478-19-000017
11/14/18	09/30/18	10-Q	0001390478-18-000035
08/14/18	06/30/18	10-Q	0001390478-18-000022
05/15/18	03/31/18	10-Q	0001390478-18-000010
04/13/18	12/31/17	10-K	0001193125-18-117053
11/09/17	09/30/17	10-Q	0001390478-17-000074
08/14/17	06/30/17	10-Q	0001390478-17-000059
05/10/17	03/31/17	10-Q	0001390478-17-000036
03/15/17	12/31/16	10-K	0001390478-17-000020
11/09/16	09/30/16	10-Q	0001390478-16-000164
08/09/16	06/30/16	10-Q	0001390478-16-000134
05/10/16	03/31/16	10-Q	0001390478-16-000110
03/10/16	12/31/15	10-K	0001390478-16-000088
11/09/15	09/30/15	10-Q	0001390478-15-000050
08/06/15	06/30/15	10-Q	0001390478-15-000037
05/07/15	03/31/15	10-Q	0001390478-15-000024
03/05/15	12/31/14	10-K	0001390478-15-000012
11/05/14	09/30/14	10-Q	0001390478-14-000063
08/11/14	06/30/14	10-Q	0001390478-14-000043
05/06/14	03/31/14	10-Q	0001390478-14-000024
04/15/16	12/31/13	10-K/A	0001390478-16-000095
03/17/14	12/31/13	10-K	0001390478-14-000016
11/06/13	09/30/13	10-Q	0001390478-13-000031
08/09/13	06/30/13	10-Q	0001390478-13-000010
05/09/13	03/31/13	10-Q	0001193125-13-211191
03/12/13	12/31/12	10-K	0001193125-13-103307
11/13/12	09/30/12	10-Q	0001193125-12-465472
11/07/13	09/30/12	10-Q/A	0001390478-13-000033
08/14/12	06/30/12	10-Q	0001193125-12-355531
05/14/12	03/31/12	10-Q	0001193125-12-231316
03/28/12	12/31/11	10-K	0001193125-12-137599
11/14/11	09/30/11	10-Q	0000950123-11-098294
08/15/11	06/30/11	10-Q	0000950123-11-077641
05/16/11	03/31/11	10-Q	0000950123-11-050942
04/15/11	12/31/10	10-K	0000950123-11-036134
11/15/10	09/30/10	10-Q	0000950123-10-105806
10/28/11	06/30/10	10-Q/A	0000950123-11-092764
08/16/10	06/30/10	10-Q	0000950123-10-078120
05/17/10	03/31/10	10-Q	0000950123-10-050536
03/31/10	12/31/09	10-K	0000950123-10-031025
11/16/09	09/30/09	10-Q	0000950123-09-063131
08/14/09	06/30/09	10-Q	0000950123-09-035364
05/15/09	03/30/09	10-Q	0000950135-09-004070
03/18/09	12/31/08	10-K	0000950135-09-001826
11/14/08	09/30/08	10-Q	0000950135-08-007278
08/14/08	06/30/08	10-Q	0000950135-08-005599
05/15/08	03/31/08	10-Q	0000950135-08-003725
04/15/08	12/31/07	NT 10-K	0000950135-08-002177
03/17/08	09/30/07	10-Q	--
08/14/08	06/30/07	10-Q	0000950135-08-005599
05/15/08	03/31/07	10-Q	0000950135-08-003725
04/15/08	12/31/06	10-K	0000950135-08-002535